1. Pink Sheet
  2. >>Market Access
  3. >>Health Technology Assessment

Melanoma Combos Get Mixed Reception From German HTA Body

 
• By Ian Schofield

Germany’s IQWiG says Mekinist plus Tafinlar offers a “considerable” added benefit in melanoma after surgery, but Braftovi plus Mektovi has not shown an additional benefit over comparator therapy in unresectable or metastatic melanoma.

Value dial
The added value of melanoma combinations is under scrutiny in Germany

Novartis’s anticancer combination, trametinib (Mekinist) plus dabrafenib (Tafinlar), offers “considerable added benefit” as adjuvant treatment in adults with stage III melanoma with a BRAF V600 mutation following complete resection of affected tissue, according to the German HTA institute, IqWiG.

IQWiG also assessed another tyrosine kinase inhibitor combination, Pierre Fabre/Array Pharma’s combination of encorafenib (Braftovi) plus binimetinib (Mektovi), which is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Health Technology Assessment

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 
• By Eliza Slawther

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.

Respiratory Treatments Hit Hardest By HTA Terminations In England

 
• By Leela Barham

Exclusive analysis by the Pink Sheet explores how non-submissions by pharmaceutical companies to England’s health technology appraisal body are impacting the availability of medicines on the National Health Service.

Why Hympavzi Secured English Funding For Hemophilia B But Not Hemophilia A

 
• By Neena Brizmohun

Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.

Spain Slashes Wait Between EU Drug Authorization And Financing Decisions

 
• By Francesca Bruce

Spanish authorities say that that timelines for drug reimbursement decisions can be improved further with the right submissions from companies.

More from Market Access